ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

infigratinib

Also written as “Infigratinib”, “BGJ398” and “infigratinib 0.128 mg/kg/day”.

Its studies are mostly in Achondroplasia · Mucopolysaccharidosis IV · Stomach Neoplasms · Cholangiocarcinoma · Urinary Bladder Neoplasms, led by 5 companies.

Drug pageInfigratinib: every studyMany companies study it; this page follows only the 17 they lead. All 30 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Dec 10, 201817 company-led studies, 3 open or runningNext primary completion: Jan 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BridgeBioits history only83 open or runningphase 3since Dec 10, 2018May 12, 2014Jan 2027phase 3 · NCT06873035
Novartis50 open or runningphase 2since Oct 28, 2013Oct 27, 2009none ahead
LianBioits history only20 open or runningphase 2since Jul 28, 2021Jul 28, 2021none ahead
Helsinn Healthcareits history only10 open or runningphase 2since Jan 12, 2022Jan 12, 2022none ahead
Pfizerits history only10 open or runningphase 2since Apr 28, 2014Apr 28, 2014none ahead

Also a collaborator on its studies: Labcorp Corporation of America.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 27, 2009First study: phase 1 study in Lung NeoplasmsFirst studyNCT01004224 · 208 enrolled · United States, Australia, Austria and more
  2. Sep 19, 2012Phase 1 study in Tumor With Alterations of the FGF-RNCT01697605 · 9 enrolled · China, Japan
  3. Aug 21, 2013Phase 1 study in Breast NeoplasmsNCT01928459 · 62 enrolled · United States, Australia, Belgium and more
  4. Oct 28, 2013Phase 2 study in GlioblastomaNCT01975701 · 26 enrolled · United States, Australia, Belgium and more
  5. Jun 6, 2014Phase 2 study in Hematologic NeoplasmsNCT02160041 · 84 enrolled · United States

TargetBeta

“Fibroblast growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
futibatinibruleOtsukaphase 310

Studies

All 5 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02160041Hematologic Neoplasms · United States2TerminatedApr 30, 201884
NCT01975701Glioblastoma · United States, Australia, Belgium and more2CompletedOct 3, 201826
NCT01928459Breast Neoplasms · United States, Australia, Belgium and more1CompletedAug 201662
NCT01697605Tumor With Alterations of the FGF-R · China, Japan1CompletedFeb 7, 20199
NCT01004224Lung Neoplasms · United States, Australia, Austria and more1CompletedOct 8, 2018208

How it is read

Names in the registry

  • “Infigratinib”, 7 entries
  • “BGJ398”, 7 entries
  • “infigratinib 0.128 mg/kg/day”, 1 entry
  • “infigratinib 0.25 mg/kg/day”, 1 entry
  • “Infigratinib 0.25 mg/kg/day”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.